トップ keyboard_arrow_right TCROSS NEWS: Global keyboard_arrow_right Japan Today

Stroke Risk Stratification by CHADS2 Score in Patients Undergoing PCI without Atrial Fibrillation: The CREDO-Kyoto Registry Cohort 3

From the CREDO-Kyoto Registry Cohort 3, an increased CHADS2 score was associated with an increased risk and severity of ischemic stroke in patients undergoing PCI, regardless of whether they had atrial fibrillation or not, reported Dr. Yuki Obayashi and colleagues from the Kyoto University Graduate School of Medicine reported in the October 15 issue of The American Journal of Cardiology.

Dr. Obayashi and colleagues included 11,516 patients with coronary artery disease undergoing PCI who were enrolled in the CREDO-Kyoto Registry Cohort 3. They then divided the patients into two groups for 721 patients with atrial fibrillation and 10,795 patients without it. The association between CHADS2 score and long-term risk of ischemic stroke and its severity was evaluated.

As CHADS2 scores increased from 0 or 1 to 6, the 5-year incidence of ischemic stroke increased progressively from 2.1% to 17.1% in patients without atrial fibrillation and from 4.2% to 40.7% in patients with atrial fibrillation. The 5-year incidence of ischemic stroke in non-atrial fibrillation patients with a CHADS2 score of 2 was numerically similar to that in atrial fibrillation patients with a CHADS2 score of 1 (3.4% vs. 3.7%).

There was no significant difference in mRS scores among the 423 patients who developed ischemic stroke according to whether they had atrial fibrillation or not (p trend=0.12). Elevated CHADS2 scores were significantly associated with higher mRS scores in both atrial fibrillation and non-atrial fibrillation patients (p trend=0.03 and p trend<0.001, respectively).

Dr. Obayashi and colleagues summarize, "Elevated CHADS2 scores were associated with increased ischemic stroke risk and severity in patients with and without atrial fibrillation."

Obayashi Y, et al. Am J Cardiol. 2022; 181: 9-17

※コンテンツには、国内で未承認、適応外の医療機器、医薬品、または効能・効果/用法・用量の情報を含む場合がありますが、未承認、適応外の使用を推奨するものではありません。

ご注意 当サイト内の全ての記事と動画の転載・転送はご遠慮ください。なお、法律上保護されたコンテンツの無許可の転載、複製、転用等は、当該コンテンツの権利者等から損害賠償請求その他の法的手続を申し立てられ、事案によっては処罰される可能性、また、故意にそれらを受け取った場合も同様の措置を受ける可能性がございます。ご不明な点がございましたら当社までご連絡ください。